- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1655501-53-3] Fremanezumab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P99019 |
| Brand: | MCE |
| CAS: | 1655501-53-3 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Fremanezumab] |
Summary
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP) . CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03303105 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
January 4, 2018 | Phase 3 |
| NCT04628429 | Medical University of Vienna |
Episodic Migraine|Chronic Migraine
|
October 1, 2020 | |
| NCT04530110 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
September 16, 2020 | Phase 3 |
| NCT03347188 | Teva Branded Pharmaceutical Products R&D, Inc. |
Post-Traumatic Headache
|
December 18, 2017 | Phase 2 |
| NCT05458011 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
August 23, 2022 | Phase 3 |
| NCT03303079 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
December 19, 2017 | Phase 2|Phase 3 |
| NCT03539393 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
||
| NCT02945046 | Teva Branded Pharmaceutical Products R&D, Inc. |
Episodic Cluster Headache
|
January 19, 2017 | Phase 3 |
| NCT05284019 | H. Lundbeck A+S |
Migraine
|
March 4, 2022 | Phase 4 |
| NCT02629861 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
March 23, 2016 | Phase 3 |
| NCT04334408 | Mayo Clinic |
Cadasil|Migraine
|
December 2021 | Phase 2 |
| NCT03107052 | Teva Branded Pharmaceutical Products R&D, Inc. |
Cluster Headache
|
April 27, 2017 | Phase 3 |
| NCT04041284 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine|Major Depressive Disorder
|
September 13, 2019 | Phase 4 |
| NCT03308968 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine Prophylaxis
|
October 13, 2017 | Phase 3 |
| NCT03303092 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
December 19, 2017 | Phase 2|Phase 3 |
| NCT04693533 | Beth Israel Deaconess Medical Center|Teva Pharmaceuticals USA |
Migraine Disorders|Sleep Disorder
|
July 29, 2021 | Phase 4 |
| NCT04464707 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
July 30, 2020 | Phase 3 |
| NCT03965091 | Teva Branded Pharmaceutical Products R&D, Inc. |
Fibromyalgia
|
May 31, 2019 | Phase 2 |
| NCT02638103 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
February 26, 2016 | Phase 3 |
| NCT05342493 | Otsuka Pharmaceutical Co., Ltd. |
Migraine Disorders
|
April 20, 2022 | |
| NCT02621931 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
March 22, 2016 | Phase 3 |
| NCT05281770 | Austrian Migraine Registry Collaboration|Medical University of Vienna|Medical University Innsbruck|Austrian Headache Society |
Migraine|Migraine With Aura|Migraine Without Aura|Chronic Migraine|Episodic Migraine
|
October 1, 2022 | |
| NCT02673567 | Teva Branded Pharmaceutical Products R&D, Inc. |
Pharmacokinetics
|
March 31, 2016 | Phase 1 |
| NCT04447729 | Teva Branded Pharmaceutical Products R&D, Inc. |
Interstitial Cystitis
|
October 15, 2020 | Phase 2 |
| NCT02964338 | Teva Branded Pharmaceutical Products R&D, Inc. |
Chronic Cluster Headache
|
January 17, 2017 | Phase 3 |
| NCT04458857 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
July 16, 2020 | Phase 3 |
Appearance
Liquid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.